Lixiana put up a great fight in NOAC market in beginning of 2nd yearly half

The Lixiana’s growth trend has drawn attention in the novel oral anticoagulant(NOAC) market in the beginning of the 2^nd yearly half. The product not only showed an increase rate among other products on July compared to June, but first outran Pradaxa on the 3^rd position in the amount of prescriptions.

According to the industry concerned on the 21^st, the amount of NOAC outpatient prescriptions o...